Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance

Executive Summary

Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.


Related Content

Diabetes Treatment Shift Coming? Cleveland Clinic’s Nissen Declares Victory
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
2Q Pharma Results Preview: What Lies Ahead
Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib
Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say
Lilly's Growth In Diabetes Gives It Market Leading Position


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts